cyrilzakka/clinical-trials huggingface dataset:
Efficacy of Travoprost/Timolol for Uncontrolled Intraocular Pressure

The purpose of this study is to demonstrate superior intraocular pressure (IOP) control with travoprost 0.004% / timolol 0.5% compared to beta-blocker monotherapy in participants with open-angle glaucoma or ocular hypertension.


Eligibility Criteria:
Inclusion Criteria:

* Have a clinical diagnosis of either open angle glaucoma or ocular hypertension.
* Currently on beta-blocker monotherapy (for \>30 days) and would benefit, in the opinion of the investigator, from further intraocular pressure (lOP) reduction.
* Have a mean baseline lOP of \>18 mmHg and \<32 mmHg in at least one eye.
* Must be able to understand and sign an Informed Consent form.
* Other protocol-specified inclusion criteria may apply.

Exclusion Criteria:

* Use of medication excluded by the protocol.
* Diseases, illnesses, infections, or ocular abnormalities excluded by the protocol.
* Ocular surgeries or procedures excluded by the protocol.
* Best-corrected visual acuity (BCVA) score worse than 55 ETDRS letters (equivalent to 20/80 Snellen, 0.60 logMAR or 0.25 decimal).
* Hypersensitivity to prostaglandin analogues or any component of the study medications in the opinion of the investigator.
* Women of childbearing potential if pregnant, test positive for pregnancy at Screening visit, breastfeeding, or not in agreement to use adequate birth control methods to prevent pregnancy throughout the study.
* Other protocol-specified exclusion criteria may apply.
Validation of Digital Chest-X-ray (CXR) to Assess Lung Recruitment in ARDS

Lung recruitability is essential for optimal Positive end-expiratory pressure (PEEP) selection in ARDS patients. It is defined as the potential for the non aerated or poorly aerated lung mass to become aerated due to the increase in airway pressure. PEEP contributes to lung recruitment mostly by maintaining some amount of the end-inspiratory recruitment at the end of expiration. PEEP also stabilizes patency of the small airways and minimizes the repeated opening and closing of them during the breathing cycle, which is implicated in a further lung inflammation. The gold-standard method for assessing lung recruitability is lung CT scan. For economic and feasibility this technique cannot be used in routine. Therefore, techniques that can be used at the bedside to measure lung recruitability are very well known. The measurement of recruited lung volume (Vrec) by using pressure-volume curve generated by the ventilator is another reference method to approach lung recruitment. It can be done at the bedside. Chest-X-Ray (CXR) is an interesting option as done in routine in this setting. Furthermore, it allows quantifying aeration thanks numerical image processing and a regional approach. In a preliminary one-center study we found a significant negative correlation between the amount of Vrec and the reduction in lung density measured by digital CXR between 5 and 15 cm H2O PEEP. In present study we would like to extend this previous result on a larger number of patients in a multicenter investigation.


Eligibility Criteria:
Inclusion Criteria:

* intubation and mechanical ventilation in the ICU
* Ramsay score 6 under sedation and analgesia
* ICU respirator implemented with pressure-volume curve device
* age equal to or greater than 18 years
* ARDS defined from the Berlin criteria
* absence of pneumothorax on the CXR before the study
* Absence of pleural effusion greater than 500 ml estimated from ultrasonography.
* no child-bearing woman
* written inform consent signed by the next of kin

Exclusion Criteria:

* Pneumothorax
* Pleural effusion greater than 500 ml estimated from ultrasonography
* Thoracic surgery in the last 3 months
* Contra-indication to CXR
* contra-indication to PEEP of 15 cm H2O
* contra-indication to PEEP of 15 or PEEP 15 mandated
* pressure-volume curve not feasible
* refusal to participate
* language barrier of the next of kin
* child-bearing woman
* person under legal protection
Prognostic Role of LA Strain in Acute Myocardial Infarction

This is a single-center retrospective observational study in which we consecutively selected patients diagnosed with acute myocardial infarction from September 2019 to March 2024 at the Affiliated Hospital of Xuzhou Medical University. Inclusion criteria: 1. CMR was completed during all hospitalizations; 2. complete clinical data; 3. received continuous cardiac monitoring during hospitalization. Exclusion criteria: 1. unclear or non-compliant CMR images; 2. previous history of myocardial infarction; 3. malignant tumors diseases. Dedicated cardiovascular imaging software CVI42 (cvi42® version 5.13.5, Circle Cardiovascular Imaging, Canada) was used for image analysis. LA strain was obtained by cardiac MRI feature tracking. Patient prognosis was obtained through chart notes and telephone follow-up. Major events included atrial fibrillation, ischemic stroke, and all-cause mortality.


Eligibility Criteria:
Inclusion Criteria:

* 1.CMR was completed during all hospitalizations; 2. complete clinical data; 3. received continuous cardiac monitoring during hospitalization.

Exclusion Criteria:

* 1.unclear or non-compliant CMR images; 2. previous history of myocardial infarction; 3. malignant tumors diseases.
Quantitative US for Evaluation of Hepatic Steatosis in NAFLD

The purpose of this study is to evaluate diagnostic performance of quantitative ultrasonographic parameters for the assessment of hepatic steatosis with find optimal cut-off values in patients with non-alcoholic fatty liver disease using magnetic resonance imaging proton density fat fraction (MRI-PDFF) and MR spectroscopy as the reference standard.


Eligibility Criteria:
Inclusion Criteria:

* patients with known NAFLD or suspected of having NAFLD
* Patients who are scheduled hepatectomy for living donor liver donation
* aged ≥ 18 years who are willing and able to complete all procedures

Exclusion Criteria:

* excessive alcohol consumption within 2 years (40g/day for men, 20g/day for women)
* clinical, laboratory, or histologic evidence of a liver disease other than NAFLD, including viral hepatitis, autoimmune hepatitis, or genetic or acquired disorders
* use of steatogenic or hepatotoxic medication
* evidence of decompensated liver disease
* history of liver surgery
* contraindication to MRI
* any other condition believed by investigator to affect a patients' compliance, or completion of the study
Dynamic Imaging of the Subtalar Instability

The purpose of this study is to describe normal dynamic computed tomography anatomy of hind foot in inversion/eversion movement, and to define diagnostic criteria for subtalar instability.

Dynamic CT (Aquilion One Toshiba) of the ankle during inversion and eversion movement will be performed in patients from three groups: healthy volunteers, patients with subtalar arthritis, and patients with suspicion of subtalar instability.

Eligibility Criteria:
Inclusion Criteria:

* Group Instability: suspicion of subtalar instability
* Group Arhtritis: subtalar stiffness
* Group Healthy volunteers: healthy volunteers
* conscious and cooperating
* written consent obtained after oral and written clear and intelligible information
* no pregnancy

Exclusion Criteria:

* pregnancy
* unable to understand information about this study
* unable to understand the movement of inversion / eversion of ankle
* absence of affiliation to social security
Norspan Versus Oxycontin as Postoperative Painkiller to Proximal Extracapsular Fractures of the Femur

Effective treatment of pain after hip fractures is very important but difficult. It is often an old patient who has many adverse effects with the use of morphine.

This is a randomized pilot study where the investigators want to compare Norspan plaster to Oxycontin tablets to patients with particular kind of hip fractures. The investigators will evaluate mobilization, pain, use of rescue medicine, adverse effects and length of stay. No clinical study about the effect of Norspan as acute painkiller has never been done before. Can the investigators get the patients mobilized earlier with less adverse effects?


Eligibility Criteria:
Inclusion Criteria:

* Males and females age 18 years or more
* X-ray confirming basicervical, pertrochanteric or subtrochanteric femur fracture and planning operation with DHS or PFN.
* Subjects must have 7 or more points in the Hindsøes test.

Exclusion Criteria:

* Subjects where spinal anaesthesia cannot be applied.
* Subject in Plavix® treatment seven days before admission to the hospital.
* Subjects with extracapsular hip fracture due to bone metastasis.
* Subjects with a BMI over 30.
* Subjects under 45 kg.
* Subjects who are currently taking monoamine oxidase inhibitors (MAOIs) or have taken MAOIs within 2 weeks prior admission to the hospital.
* Substance or alcohol abuse, or subjects who, in the opinion of the investigator have demonstrated addictive or substance abuse behavior.
* Untreated depression or other psychiatric disorder in such a way that participation in the study may in the opinion of the investigator pos an unacceptable risk to the subject.
* Dermatological disorder at any relevant patch application site.
* Any contraindications listed in the Summary of Product Characteristics for Norspan®, OxyNorm® and OxyContin®.
* Patient does not tolerate oxynorm.
* User of wheelchair.
* Daily use of morphine before hospitalization.
* More than one fracture. Patients with myasthenia gravis. Patients with severe respiratory function. Patients know need re-operation women of childbearing potential must have a negative pregnancy test and be non-lactating
Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients

This study represents the first investigation of anrukinzumab in patients with active ulcerative colitis (UC) and will evaluate proof of mechanism by changes in the mechanism based biomarker (YKL 40) and pharmacodynamic biomarkers (fecal calprotectin, lactoferrin and hs-CRP). It will provide further assessment of the safety, tolerability, and pharmacokinetics (PK) by administration of multiple intravenous (IV) doses of anrukinzumab.


Eligibility Criteria:
Inclusion Criteria:

* Male or Female, Age \>=18 and \<=65 years
* Active ulcerative colitis (UC) beyond the rectum based upon Mayo Score
* women of childbearing potential with highly effective method of contraception

Exclusion Criteria:

* Indeterminate disease status, Crohn's disease, ischemic colitis, positive HIV, positive or history of tuberculosis infection, active enteric infections, transplant organ recipient, concomitant steroids, immunosuppressives or anti-TNFs.
Effectiveness of a Physical Activity and Diet Program in Patients With Psychotic Disorder (CapiCor)

The aim is to evaluate the effectiveness of an intervention based on a program of physical activity and diet coordinated between primary care teams (PCT) and Mental Health Centres (MHC) to modify the weekly physical activity (PA) amount, body mass index (BMI) and waist circumference in patients with severe mental disorder diagnoses. To assess changes in cardiovascular risk, quality of life and lifestyles, secondarily. Methods: A randomized clinical trial with a control group, of one year of follow-up, carried out in four MHC Barcelona and Santa Coloma, and PCT of reference. The investigators studied patients aged 18 - 65 years old, diagnosed with schizophrenia, schizoaffective or bipolar disorder, with antipsychotic medication and a low level of PA. 240 patients will be selected in each group (difference to be detected in the BMI:\> 1.89 kg/m2; common SD: 6.2, 30% loss). Intervention: group educational PA program (basically walking) of 24 sessions over 12 weeks, and diet (8 sessions in the first 8 weeks) by nurses and specialists in PA. Key measurements: level of PA (IPAQ questionnaire), physical examinations: BMI, waist circumference, blood pressure, cardiovascular risk, quality of life (SF-36), smoking habits, dietary habits (PREDIMED questionnaire), analytical parameters: cholesterol , triglycerides, blood glucose. Evaluations will be masked and conducted at 0, 3, 6 and 12 months. Analysis of variance for repeated measures to adjust for differences attributable to the effect of the intervention for potential confounders: pharmacological treatment, care level of intervention and mental state.


Eligibility Criteria:
Inclusion Criteria:

* age between 18 and 65 years old,
* understand Catalan or Spanish
* will be located for at least twelve months.
* Psychiatric disorders with ICD-10 diagnosis codes: F20\*, F31\* and F25\*.
* Taking an antipsychotic drug at, a least, three months
* Low physical activity level

Exclusion Criteria:

* Active addiction to psychoactive drugs, except tobacco.
* Pregnancy
* Diseases that doesn't allow physical activity
* Psychotic acute exacerbation in the last month
A Long-term Safety Study of Once-daily Travatan

Long term safety study of TRAVATAN in patients with Open-angle glaucoma or ocular hypertension.


Eligibility Criteria:
Adult patients of any race and either sex with chronic angle-closure glaucoma.
Comparison of 3 Different Density Levobupivacaine Solutions + Fentanyl for Spinal Anaesthesia for Caesarean Delivery.

The investigator's aim is to compare the efficacy of 3 levobupivacaine solutions with different density on spinal anesthesia for caesarean delivery.

Patients scheduled for elective caesarean delivery were separated into 4 groups. Spinal anesthesia was performed with one of the following regimens.

Group 1: Levobupivacaine 8 mg + 20 mcg Fentanyl Group 2: Levobupivacaine 8 mg + 20 mcg Fentanyl + 40 mg Dextrose Group 3: Levobupivacaine 8 mg + 20 mcg Fentanyl + 60 mg Dextrose Group 4: Levobupivacaine 8 mg + 20 mcg Fentanyl + 80 mg Dextrose After anesthesia induction motor block was evaluated via bromage scale and sensory block via pinprick test every 3 minutes for the first 15 minutes, and every 5 minutes up to 60 minutes. Maximum sensory block level, time to reach maximum block level, time needed to achieve T10 sensory level were recorded.

Baby delivery time, and operation duration were also recorded. Time to two segment regression of maximum sensory block, motor block recovery time and time to S2 regression of sensory block will be recorded.

Hemodynamic data, nausea vomiting, were also recorded throughout surgery at the same evaluation periods and postoperative period.

The surgeon will also evaluate the abdominal relaxation surgical block quality as good, medium and poor.

The patient will evaluate spinal block analgesia quality as good, medium or poor.

Pain scores are going to be evaluated by VAS at the beginning, uterine incision and during abdominal closure. Time for first analgesic requirement and postoperative pain is also going to be evaluated by VAS.

Eligibility Criteria:
Inclusion Criteria:

* ASA I-II
* Pregnancy at Term
* Scheduled for elective caesarean delivery

Exclusion Criteria:

* contraindication for spinal anesthesia
* drug allergy
* pregnancy related disorders (hypertension, placenta previa, fetal problems)
Newborn Abdominal Massage to Prevent Hyperbilirubinemia

The proposed study will incorporate an intervention previously un-studied in the US healthcare setting for prevention of hyperbilirubinemia


Eligibility Criteria:
Inclusion Criteria:

* Newborn admitted to the well newborn/postpartum care unit at UC Davis Medical Center
* Less than 48 hours of age at enrollment

Exclusion Criteria:

* Infant has already received phototherapy
* Mother/birthing person is incarcerated
* Infant unexpected to discharge into parental care
* Parental inability to speak or read in English
* Infant without parent rooming-in with them in the hospital
Laser Speckle Flowgraphy in Caucasians: Age Dependence and Comparison With Doppler Optical Coherence Tomography

Some of the most prevalent eye diseases such as age-related macular degeneration, glaucoma and diabetic retinopathy are associated with ocular perfusion abnormalities. Currently, there is no gold-standard method for the measurement of ocular blood flow available. Laser speckle flowgraphy is a promising technique for the two-dimensional assessment of ocular blood flow in humans. So far the technique has, however, been only gained widespread use in Japan. The experience in Caucasian subjects is very limited. In a Japanese population it was shown that mean blur rate, a measure of chorioretinal blood velocity, decreases with age. This is of relevance, because an age-related decline in ocular blood flow may partially explain the age-dependence of ocular vascular disease. The present study investigates this age-dependence in healthy subjects. In addition, the investigators investigate in a sub-group of this population whether relative flow volume (RFV), a novel index of blood flow in the human retina derived from laser speckle flowgraphy is associated with retinal blood flow as assessed with bi-directional Doppler Optical Coherence Tomography (DOCT).


Eligibility Criteria:
Inclusion Criteria:

* Men and women aged over 18 years, nonsmokers
* Subject is generally healthy with no current significant or a history of a significant neurological, cardiovascular, pulmonary (including asthma), hepatic, metabolic, rheumatic, autoimmune, hematological or renal disorder, as determined by the investigator's clinical judgment through collection of medical history and performance of a physical examination. A significant disorder is defined as a disease or medical condition associated with impaired health status, requiring regular or current medical treatment and/or follow up. For the purposes of this study, an investigator may classify a medical condition as a nonsignificant disorder despite the fact that the subject receives treatment. Subjects having controlled Stage 1 hypertension (blood pressure of 140-159 mmHg systolic and/or 90- 99 mmHg diastolic) are eligible for participation in this study.
* Normal ophthalmic findings, ametropia \< 6 Dpt

Exclusion Criteria:

* Symptoms of a clinically relevant illness in the 3 weeks before the first study day
* Wearing of contact lenses
* Ocular infection or clinically significant inflammation
* Ocular surgery in the 3 months preceding the study
* Blood donation in the 3 weeks preceding the study
* Pregnancy, planned pregnancy or lactating
* Opacities of the cornea (e.g. corneal scars, corneal oedema), the lens (e.g. Lens opacities classification system version II (LOCS-II) grading \> 2, posterior capsule opacification) or the vitreous (e.g. vitreous haemorrhage, asteroid hyalosis)
Symbicort in Airway Predominant Chronic Obstructive Pulmonary Disease (COPD)

The main objective of the study is to see if using anti-inflammatory to patients with airway disease chronic obstructive pulmonary disease (COPD) phenotype will be more effective than using these treatments in patients with loss of lung tissue. Symbicort plus ipratropium/albuterol will be used for 12 weeks in an open-label study in subjects with airway predominant COPD.

Subjects from the COPDGene study who have airway-predominant COPD on chest CT scan will be enrolled; a total of 40 subjects is planned.

Subjects will all have background ipratropium-albuterol administered four times daily. Subjects will be randomized to receive budesonide (180 ug twice daily) or formoterol-budesonide (160/4.5 ug twice daily) for 12 weeks.

The main objective is to explore novel outcomes: blood biomarkers and chest CT scan. Outcomes include lung function, walk distance, respiratory disease-specific health status, and expiratory chest CT scan gas trapping as an exploratory outcome.

The primary outcome measure will be FEV1 pre-bronchodilator 12 hours after the last dose of study medication at the end of 12 weeks of treatment. FEV1 will be measured in the morning 6 hours after the last dose of ipratropium/albuterol and 12 hours after the last dose of budesonide and budesonide/formoterol

Eligibility Criteria:
Inclusion Criteria:

1. COPD GOLD Stage 2 and 3 (post-bronchodilator FEV1 35-80% predicted and FEV1/FVC \<0.7 at the time of enrollment in COPDGene) by spirometry.
2. Less than 15% of the lung \<-950 Hounsfield Units on COPDGene high-resolution inspiratoryChest CT scan (i.e. no evidence of significant emphysema)
3. Greater than 10% gas trapping on COPDGene expiratory CT scan (i.e. evidence of small airway disease).
4. No history of recent use (within the pat 8 weeks) of an inhaled or systemic corticosteroid.
5. Body weight \<100 kg (low dose CT scans in subject with increased boyd weight can not be reliably analyzed).

Exclusion Criteria:

1. Exacerbation of COPD or other respiratory illness requiring antibiotics within the past 8 weeks.
2. Previous adverse reaction to inhaled steroids, long-acting beta agonists, or long-acting anticholinergic medications.
3. Symptomatic, untreated benign prostate hypertrophy.
4. Allergy to peanuts.
5. Glaucoma
Couples Dynamics and Smoking Cessation

This study is about investigating smoking and attempts to quit smoking in couples. Participation will help determine better treatment efforts for couples who want to quit smoking. All study procedures will be conducted remotely, allowing couples to interact with study personnel through zoom.


Eligibility Criteria:
Inclusion Criteria:

* Couples must be in a relationship for more than 6 months with no plans to separate or move in the next 30 days.
* Participants must smoke at least 5 cigarettes per day for at least the past 2 years.

Exclusion Criteria:

* English non-fluency.
* Currently pregnant, nursing, or intend to become pregnant within the next 6 months.
Transcranial Doppler in Mild and Moderate Traumatic Brain Injury (TBI)

Utility of transcranial Doppler as an Early Predictor of Neurological deterioration in Mild and Moderate Traumatic Brain Injury

Transcranial Doppler done to TBI patients on admission and follow up was done and Secondary Neurological deterioration was documented

Eligibility Criteria:
Inclusion Criteria:

* patient with traumatic brain injury and glasgow coma scale 9_15

Exclusion Criteria:

Unstable or patient on Mechanical ventilation, Sever brain injury , patient receive anticoagulant